PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.
Mol Cancer Ther. 2018 Feb 13;:
Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R
Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.